| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
CDK2 60 nM (IC50)
CDK2-IN-3 targets cyclin-dependent kinase 2 (CDK2). CDK2 is an essential enzyme that regulates the cell cycle transition from G1 to S phase. By inhibiting CDK2, the compound blocks cell cycle progression and inhibits cell proliferation. The compound is a potent and selective CDK2 inhibitor with an IC50 of 60 nM. It is widely used in cancer research. |
|---|---|
| ln Vitro |
In cell-free biochemical assays, CDK2-IN-3 inhibits CDK2 with an IC50 of 60 nM. This activity demonstrates the compound's potent and direct inhibition of CDK2 enzymatic activity. The compound's selectivity for CDK2 over other CDKs can be assessed using kinase profiling assays. The compound is widely used in cancer research to study CDK2-dependent signaling.
|
| ln Vivo |
In cell-based assays, CDK2-IN-3 inhibits CDK2 activity, leading to cell cycle arrest and inhibition of cell proliferation. The compound (12 μM, 24 hours) significantly protects CCL64 mink lung epithelial cells from various chemotherapeutic drugs such as Taxol and 5-FU. This suggests a potential role in protecting normal cells from chemotherapy-induced toxicity. The compound is used in cancer research.
|
| Enzyme Assay |
The cell-free assay for CDK2 inhibition involves measuring the kinase activity of purified CDK2-cyclin complex in the presence of the compound. The assay uses a peptide substrate and ATP, and the phosphorylation of the substrate is measured using radioactivity, fluorescence, or luminescence. The IC50 of 60 nM is determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for CDK2-IN-3 involve culturing cancer cell lines and treating them with the compound at concentrations ranging from 0.01 to 100 μM. Cells are incubated for 24-72 hours, and cell viability is assessed using MTT or CCK-8 assays. Cell cycle analysis is performed by flow cytometry. The compound's protective effects on normal cells from chemotherapy-induced toxicity are assessed in relevant cell models.
|
| Animal Protocol |
In animal models, CDK2-IN-3 could potentially be evaluated for its anti-tumor activity and its ability to protect normal cells from chemotherapy-induced toxicity. Typical studies involve administration of the compound to tumor-bearing mice via intraperitoneal or oral routes. Tumor growth, cell cycle markers, and toxicity are assessed. The compound's protective effects on normal tissues are evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CDK2-IN-3 have not been extensively reported. As a small molecule with a molecular weight of 395.23 g/mol, the compound would be expected to have moderate oral bioavailability and tissue penetration. The compound is typically stored at -20°C, protect from light. Further pharmacokinetic studies would be required.
|
| Toxicity/Toxicokinetics |
CDK2-IN-3 is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent. As a CDK2 inhibitor, the compound may have effects on normal dividing cells as well as cancer cells. Standard toxicity studies in rodents would be required to determine the safety profile.
|
| References | |
| Additional Infomation |
CDK2-IN-3 is a research-grade compound supplied for cancer research. It is not an approved pharmaceutical and has no clinical trial history. The compound is a potent and selective CDK2 inhibitor with an IC50 of 60 nM. It is widely used to study CDK2-dependent signaling and therapeutic interventions in tumors. This product is intended for research use only.
|
| Molecular Formula |
C14H11BRN4O3S
|
|---|---|
| Molecular Weight |
395.23
|
| Exact Mass |
393.973
|
| CAS # |
222035-13-4
|
| PubChem CID |
3551941
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Index of Refraction |
1.769
|
| LogP |
2.53
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
545
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1N=NC2=C(NC3=C2C=C(C=C3)Br)O)S(=O)(=O)N
|
| InChi Key |
IWDDMLCHUYBHHD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H11BrN4O3S/c15-8-1-6-12-11(7-8)13(14(20)17-12)19-18-9-2-4-10(5-3-9)23(16,21)22/h1-7,17,20H,(H2,16,21,22)
|
| Chemical Name |
4-[(5-bromo-2-hydroxy-1H-indol-3-yl)diazenyl]benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~253.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5302 mL | 12.6509 mL | 25.3017 mL | |
| 5 mM | 0.5060 mL | 2.5302 mL | 5.0603 mL | |
| 10 mM | 0.2530 mL | 1.2651 mL | 2.5302 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
